Loading...
Market
How will the market react to Sarepta and Arrowhead's collaboration by March 31, 2025?
3
Resolution / Starting Odds
Sarepta stock up >10% • 25%
Arrowhead stock up >10% • 25%
Both stocks up >10% • 25%
Neither stock up >10% • 25%
Stock market data and financial reports
Story
Sarepta and Arrowhead Pharmaceuticals Announce $825 Million siRNA Collaboration with $500 Million Upfront and $325 Million Equity
Nov 26, 2024, 12:11 PM
Sarepta Therapeutics has entered into a global licensing and collaboration agreement with Arrowhead Pharmaceuticals, focusing on multiple clinical and preclinical small interfering RNA (siRNA) programs. The deal is valued at $825 million, with Arrowhead set to receive $500 million upfront and an additional $325 million through equity investment at a 35% premium. This partnership allows Sarepta to diversify its research beyond its traditional focus on Duchenne muscular dystrophy (DMD) to include fibrosis and neurological conditions. The collaboration includes several specific programs, such as ARO-DUX4 for facioscapulohumeral muscular dystrophy and ARO-MMP7 for idiopathic pulmonary fibrosis. The agreement reflects a growing trend of collaboration between biotech companies, as they seek to leverage each other's strengths in developing innovative therapies.
View original story
Similar markets
Relationship improves • 25%
Relationship deteriorates • 25%
Relationship remains the same • 25%
No official statement • 25%
Yes • 50%
No • 50%
Stock price up 0-10% • 33%
Stock price up 10-20% • 33%
Stock price up more than 20% • 34%
Positive response • 25%
Neutral response • 25%
Negative response • 25%
Mixed response • 25%
Mostly positive • 25%
Mostly negative • 25%
Mixed • 25%
Neutral • 25%
Below $166 • 33%
$166 to $213 • 33%
Above $213 • 34%